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Abstract: The involvement of microRNAs in the control of repressors of human γ-globin
gene transcription has been firmly demonstrated, as described for the miR-486-3p mediated
down-regulation of BCL11A. On the other hand, we have reported that miR-210 is involved in
erythroid differentiation and, possibly, in γ-globin gene up-regulation. In the present study, we
have identified the coding sequence of BCL11A as a possible target of miR-210. The following
results sustain this hypothesis: (a) interactions between miR-210 and the miR-210 BCL11A site were
demonstrated by SPR-based biomolecular interaction analysis (BIA); (b) the miR-210 site of BCL11A
is conserved through molecular evolution; (c) forced expression of miR-210 leads to decrease of
BCL11A-XL and increase of γ-globin mRNA content in erythroid cells, including erythroid precursors
isolated from β-thalassemia patients. Our study suggests that the coding mRNA sequence of BCL11A
can be targeted by miR-210. In addition to the theoretical point of view, these data are of interest
from the applied point of view, supporting a novel strategy to inhibit BCL11A by mimicking miR-210
functions, accordingly with the concept supported by several papers and patent applications that
inhibition of BCL11A is an efficient strategy for fetal hemoglobin induction in the treatment of
β-thalassemia.
Keywords: microRNAs; miR-210; BCL11A; hemoglobin; erythroid differentiation; β-thalassemia;
γ-globin
1. Introduction
MicroRNAs (miRNAs, miRs) are a category of conserved, short (19 to 25 nucleotides in
length) RNAs that regulate gene expression by targeting specific mRNA sequences [1–3], causing a
post-transcriptional negative control or mRNA degradation, depending on the level of base-pairing
between miRNAs and target RNA sequences [1,4,5]. Since their discovery and first characterization, the
number of validated microRNA sequences enlisted in databases has significantly grown [3]. Moreover,
considering that a mRNA might contain in its 3′ untranslated region (3′UTR), coding DNA sequence
(CDS), 5′ untranslated region (5′UTR) several sequences for miRNA recognition and that a single
miRNA can bind and regulate several mRNAs, it is calculated that more than 60% of human mRNAs
are targets of microRNAs [2,4]. Therefore, a great interest is concentrated on the study of validated
miRNA targets. Considering the role of microRNAs, low expression of a given miRNA is expected
to be linked with an accumulation of the target mRNAs; conversely, high expression of miRNAs is
expected to be associated with low expression of the target mRNAs.
Int. J. Mol. Sci. 2017, 18, 2530; doi:10.3390/ijms18122530 www.mdpi.com/journal/ijms
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In this respect, increasing numbers of reports about the roles of microRNAs in erythropoiesis
have been published [6–18]. For instance, Felli et al. identified miR-221 and miR-222 as being
highly expressed in human cord blood-derived hematopoietic CD34+ progenitor cells [6]. MicroRNA
expression profiling was also performed by Choong et al. on ex vivo differentiating erythroid cultures
derived from human umbilical cord blood (UCB) CD34+ cells and K562 cells, with the aim of identifying
miRNAs involved in erythropoiesis [7]. After comparison of stimulated UCB-derived CD34+ cells
and K562 cells, several miRNAs were identified putatively critical for erythroid development and
maturation. MicroRNAs miR-15b, miR-16, miR-22, and miR-185 were found to have strong positive
correlation with the appearance of erythroid surface antigens (CD71, CD36, and CD235a) and
hemoglobin synthesis, while miR-28 displayed an inverse relationship with the expression of these
markers [7]. Other efforts aimed at defining erythroid-specific miRNAs were those published by
Georgantas et al., who demonstrated miR-155 as a microRNA involved in the control of both myeloid
and erythroid differentiation [8]. In conclusion, miRNAs have been indicated to play roles in
normal hematopoiesis [6–18].
We have previously reported the following observations on miR-210: (a) miR-210 expression
is high in erythroid precursors from β-thalassemia patients displaying high production of fetal
hemoglobin (HbF) and effective response to HbF inducers; (b) miR-210 increases following
mithramycin (MTH) treatment of K562 cells and human erythroid progenitors from normal and
β-thalassemic subjects; (c) this increase is associated with erythroid induction and elevated expression
of γ-globin genes; (d) an anti-miR against miR-210 interferes with the mithramycin-induced changes of
gene expression [19,20]. The involvement of miR-210 in erythroid differentiation was also reported by
Sarakul et al. [21], Bavelloni et al. [22] and Sawant et al. [23].
Recently, the network between microRNAs and transcription factors has been the object of
several studies, confirming the fact that it can be deeply involved in the expression of HbF
production in erythroid cells [24,25]. In this respect, there is a general agreement on two key issues:
(a) the expression of the γ-globin genes is under a strong negative control which is regulated by
transcription repressors [24–32] and (b) some of the transcription repressors are targets of several
microRNAs [24,25,33–36]. For instance, transcription factors involved in transcriptional repression
of the γ-globin genes are Oct-1 [26], MYB [27], KLF-1 [28], BCL11A [29,30] and LYAR [31,32].
The identification of microRNAs targeting mRNAs coding for these repressors (data are available for
microRNAs miR-15a, miR-16-1, miR-486-3p, miR-23a/27a) [33–35], could be useful to develop novel
approaches for the treatment of β-thalassemia [36].
The objective of the present paper was to identify possible binding of miR-210 to transcription
repressors and verify its possible function. As first putative target, the BCL11A (B-cell
lymphoma/leukemia 11A) was selected in consideration of the fact that it belongs to a complex
(constituted also by Sox6, GATA-1, Fog-1, Mi-2/NuRD complex) [29,30] deeply involved in repression
of the γ-globin gene transcription. In particular, the BCL11A-XL isoform has been firmly associated
with high β-globin gene expression and low γ-globin production [29], fully sustaining the concept that
BCL11A (particularly the XL-isoform) is a major transcriptional repressor of γ-globin gene expression.
2. Results
2.1. Presence of miR-210 Binding Sites within mRNA Sequences Coding Repressors of γ-Globin Gene
Transcription: The Coding Sequence of BCL11A mRNA Contains a Putative miR-210 Binding Site
Figure 1 shows the location of the putative miR-210 binding site within the BCL11A mRNA
coding sequence, as found employing miRWalk 2.0, a database on predicted and validated microRNA
targets (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk/), as well as inspection of the recent
published paper by Fasanaro et al. [37], describing an integrated approach to identify miR-210 binding
sites within mRNA sequences. The extent of complementarity between the human BCL11A sequences
(NM_022893) with mature miR-210 is 72.7%, and is located at nucleotides 789–798, with a predicted
seed length of 10, and a 0.0024 p-value. The location of the miR-210 binding site is within the BCL11A
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mRNA coding sequence and exhibits partial single stranded secondary structure interaction (RNAfold
WebServer, http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi).
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miR-210 and other validated miR-210-target mRNAs (Figure 2A), such as PLK1 (polo-like kinase 1: 
11 C-G or U-A and 4 G-U), ROD1 (Regulator of Differentiation 1: 15 C-G or U-A and 2 G-U) and E2F3 
(E2F transcription factor 3: 12 C-G or U-A and 2 G-U) as elsewhere published [38–40]. 
 
Figure 1. Computer-aided analysis of the possible pairing interaction between hsa-miR-210
(entry: http://www.mirbase.org/cgi-bin/mature.pl?mature_acc=MIMAT0000267) and BCL11A
mRNA (http://www.ncbi.nlm.nih.gov/nuccore/NM_022893.3). The MirWalk prediction database
and the RNAfold WebServer (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi) were used. In the
upper part of the panel, the complementarity between miR-210 and BCL11A mRNA miR-210 site is
shown, in the lower part the magnification of the stem-loop secondary structure possible interactions.
This homology (13 C-G or U-A and 3 G-U) is similar or even higher than the homology between
miR-210 and other validated miR-210-target mRNAs (Figure 2A), such as PLK1 (polo-like kinase 1:
11 C-G or U-A and 4 G-U), ROD1 (Regulator of Differentiation 1: 15 C-G or U-A and 2 G-U) and E2F3
(E2F transcription factor 3: 12 C-G or U-A and 2 G-U) as elsewhere published [38–40].
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2.2. Interaction of miR-210 with BCL11A Sequences Mimicking the miR-210 Binding Site of BCL11A 
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The ability of miR-210 to specifically interact with miR-210 binding site of BCL11A mRNA has 
been validated by SPR-based analysis with the Biacore™ X100 biosensor (Figure 2B). A biotinylated 
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between these two sequences (compare RUres with RUfin values). In fact, the extent of homology 
between miR-210 and the BCL11A miR-210 binding site is 59.1%. When the Biacore experiment was 
repeated injecting a 100% homologous RNA or DNA sequence (for nucleotide sequences see Table 1) 
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2.2. Interaction of miR-210 with BCL11A Sequences Mimicking the miR-210 Binding Site of BCL11A mRNA
The ability of miR-210 to specifically interact with miR-210 binding site of BCL11A mRNA
has been validated by SPR-based analysis with the Biacore™ X100 biosensor (Figure 2B).
A biotinylated oligonucleotide mimicking the miR-210 binding site within BCL11A mRNA (sequence:
5′-biot-GTTTCTCTTGCAACACGCACAG-3′) was immobilized on a SA sensor chip and miR-210,
miR-221 (control #1) and miR-222 (control #2) were injected obtaining the sensorgrams shown in
Figure 2B. The interaction between miR-210 and the immobilized BCL11A(miR-210) oligonucleotide
occurs within seconds, while miR-221 and miR-222 sequences did not bind. Interestingly, the hybrid
miR-210/BCL11A(miR-210) was not fully stable, as expected from the lack of 100% complementarity
between these two sequences (compare RUres with RUfin values). In fact, the extent of homology
between miR-210 and the BCL11A miR-210 binding site is 59.1%. When the Biacore experiment was
repeated injecting a 100% homologous RNA or DNA sequence (for nucleotide sequences see Table 1)
the sensorgrams included in Figure 2C were obtained, clearly showing that in this case the generated
hybrid is fully stable (RUres values almost identical to RUfin). Altogether, these data indicate that
miR-210 is able to target the BCL11A miR-210 binding site, generating however, at least in these
experimental conditions, unstable hybrids (unlike fully complementary DNA and RNA sequences).
Table 1. Oligonucleotides sequences used in Biospecific Interaction Analysis.
Name Sequence 5′–3′ Accession No. Location
BCL11A biot-GTT TCT CTT GCA ACA CGC ACA G 1 NM_022893.3 2 789–798
DNA aBCL11A CTG TGC GTG TTG CAA GAG AAA C NM_022893.3 2 789–798
RNA aBCL11A CUG UGC GUG UUG C A G AA C NM_022893.3 2 789–798
miR-210 CUG UGC GUG UGA CAG CGG CUG A MIMAT0000267 3 -
miR-221 AGC UAC AUU GUC UGC UGG GUU UC MIMAT0000278 3 -
miR-222 AGC AC AUC UGG CUA CU GG MIMAT0000279 3 -
1 biot: biotinylated; 2 http://www.ncbi.nlm.nih.gov/nuccore; 3 http://www.mirbase.org.
2.3. The miR-210 Putative Binding Sites of BCL11A Are Conserved through Molecular Evolution
The entire sequence of the BCL11A gene, despite being to some extent conserved, displays some
variations in different species, such as human (Homo sapiens), Sumatran orangutan (Pongo abelii), bovine
(Bos taurus), mouse (Mus musculus), rat (Rattus norvegicus), red junglefowl (Gallus gallus), western
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clawed frog (Xenopus tropicalis). However, as reported in Figure 3A, the BCL11A miR-210 site is highly
conserved. This miR-210 binding site covers the nucleotide region 789–798 of the BCL11A mRNA,
which is common to all the BCL11A isoforms (see Figure 3B). Interestingly, the nucleotide sequences
surrounding the BCL11A miR-210 site exhibit some nucleotide variation. These observations clearly
support the hypothesis that miR-210 plays a role in regulating the expression of the BCL11A gene
through a direct binding to the coding sequence of BCL11A mRNA. Since the location of the miR-210
binding site occurs in a region common to all the BCL11A isoforms, we hypothesize that it could be
important for post-transcriptional regulation of the general expression of BCL11A gene, including the
overall amount of produced BCL11A-XL isoform.
Int. J. Mol. Sci. 2017, 18, 2530 5 of 17 
 
2.3. The miR-210 Putative Binding Sites of BCL11A Are Conserved through Molecular Evolution 
The entire sequence of the BCL11A gene, despite being to some extent conserved, displays some 
variations in different species, such as human (Homo sapiens), Sumatran orangutan (Pongo abelii), 
bovine (Bos taurus), mouse (Mus musculus), rat (Rattus norvegicus), red junglefowl (Gallus gallus), 
western clawed frog (Xenopus tropicalis). However, as reported in Figure 3A, the BCL11A miR-210 
site is highly conserved. This miR-210 binding site covers the ucleotide region 789–798 of the 
BCL11A mRNA, which is common to all the BCL11A isoforms (see Figure 3B). Interestingly, the 
n cleoti e sequences surrounding the BCL11A miR-210 site exhibit some nucleotide variation. These 
observations clearly support the hypothesis that miR-210 plays a role in regulating the expression of 
t e BCL11A gene through a direct binding to the coding sequence of BCL11A mRNA. Since the 
location of the miR-210 binding site occurs in a region common to all the BCL11A isoforms, we 
hy thesize that it could be important for p st-transcriptional regulation of the e eral expression 
f BCL11A ge e, inclu ing the overall amount of produced BCL11A-XL isoform. 
 
Figure 3. (A) The miR-210 binding site of BCL11A is conserved through evolution. The sequences of 
human (Homo sapiens, NM_022893.3, nucleotides 789–798), Sumatran orangutan (Pongo abelii, 
XM_002812009.2, nucleotides 709–718), bovine (Bos taurus, NM_001076121.1, nucleotides 787–796), 
mouse (Mus musculus, NM_016707.3, nucleotides 896–905), rat (Rattus norvegicus, NM_001191683.1, 
nucleotides 803–812), red junglefowl (Gallus gallus, NM_001031031.1, nucleotides 812–821), frog 
(Xenopus tropicalis, NM_001079189.1, nucleotides 592–601) are indicated. Nucleotide variations with 
respect to H. sapiens BCL11A sequences are boxed; (B) Location of the miR-210 binding site within the 
BCL11A isoforms. 
2.4. Decrease of BCL11A-XL and Increase of γ-Globin after Transfection of a K562(BCL11A-XL) Clone with 
Pre-miR-210  
In order to obtain information on the biological effects of miR-210 on BCL11A-XL regulated 
genes, a K562(BCL11A-XL) clone (clone #12) was employed. The K562(BCL11A-XL) clone #12 was 
chosen because expresses at very high level BCL11A-XL (Figure 4A, in which RT-qPCR, left side of 
Figure 3. (A) The miR-210 binding site of BCL11A is conserved through evolution. The sequences
of human (Homo sapiens, NM_022893.3, nucleotides 789–798), Sumatran orangutan (Pongo abelii,
XM_002812009.2, nucleotides 709–718), bovine (Bos taurus, NM_001076121.1, nucleotides 787–796),
mouse (Mus musculus, NM_016707.3, nucleotides 896–905), rat (Rattus norvegicus, NM_001191683.1,
nucleotides 803–812), red junglefowl (Gallus gallus, NM_001031031.1, nucleotides 812–821), frog
(Xenopus tropicalis, NM_001079189.1, nucleotides 592–601) are indicated. Nucleotide variations with
respect to H. sapiens BCL11A sequences are boxed; (B) Location of the miR-210 binding site within the
BCL11A isoforms.
2.4. Decrease of BCL11A-XL and Increase of γ-Globin after Transfection of a K562(BCL11A-XL) Clone
with Pre-miR-210
In order to obtain information on the biological effects of miR-210 on BCL11A-XL regulated
genes, a K562(BCL11A-XL) clone (clone #12) was employed. The K562(BCL11A-XL) clone #12 was
chosen because expresses at very high level BCL11A-XL (Figure 4A, in which RT-qPCR, left side of
the panel, and Western blotting analysis, middle and right side of the panel, are shown) and it is
resistant to the induction of erythroid differentiation following treatments with rapamycin (RAPA),
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resveratrol (RSV), butyric acid (BA) and hydroxyurea (HU) [41]. For the production of K562 cell
clones with integrated copies of a BCL11A-XL expressing vector we have transfected K562 cells with
the pCDNA3.1-BCL11A-XL vector, and then cloned the transfected cells by limiting dilutions. As a
representative example, results of treatments of original K562 cell line and K562(BCL11A-XL) clone #12
with HU and MTH are shown in Figure 4B, demonstrating that both treatments lead to a clear increase
of the proportion of benzidine-positive cells only when the K562 cell line is employed; in fact, when
the K562(BCL11A-XL) clone #12 was used, a low but significant increase of the proportion of benzidine
positive cells was obtained with only MTH. The production and characterization of K562(BCL11A-XL)
clones have been reported elsewhere by Finotti et al. showing that untreated K562(BCL11A-XL) clone
#12 expresses lower amounts of γ-globin mRNA with respect to K562 cells [41], possibly caused by the
high levels of BCL11A-XL accumulation. As expected and reported in Figure 4C, this clone expresses,
with respect to K562 cells, low level of γ-globin genes, either in the absence or in the presence of
MTH, which, in any case, is able to partially rescue the γ-globin gene expression, suggesting that
K562(BCL11A-XL) clones are able to differentiate when treated with HbF inducers inhibiting BCL11A
expression (such as mithramycin) [41].
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Figure 4. (A) Molecular and phenotypic characterization of the K562(BCL11A-XL) clone #12. Left: level
of expression of BCL11A-XL mRNA, as determined by RT-PCR analyses of RNA isolated from the
original K562 cells and the K562(BCL11A-XL) clone #12. Middle and right panels: Western blotting
analysis showing differential expression of BCL11A-XL in K5 cells and K562(BCL11A-XL) clone #12,
as indicated; (B) benzidine staining of K562 cells and K562(BCL11A-XL) clone #12 cells treat d for
6 days with 175 µmol/L hydroxyurea (HU) r 30 nmol/L mithramycin (MTH). Benzidine-positive
cells of K562(BCL11A-XL) clone #12 are arrowed. Pictures were obtained using 20X magnification;
(C) level of expression of γ-globin mRNA, as determined by RT-PCR analyses of RNA isolated from
the original K562 cells and the K562(BCL11A-XL) clone #12 cultured for 5 days in the absence (−) or in
the presence (MTH) of 30 nM mithramycin. ** p < 0.01; * p < 0.05 (n = 5).
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Figure 5A,B shows that transfection of K562(BCL11A-XL) clone #12 cells with pre-miR-210 leads
to a sharp concentration dependent decrease of BCL11A transcripts (Figure 5A) and, at the same time,
an increase of γ-globin mRNA content (Figure 5B). In order to validate these observation at the protein
level, BCL11A protein production by K562(BCL11A-XL) clone #12 cells transfected with pre-miR-210,
was studied and the results, presented in Figure 5C, demonstrate a significant decrease of BCL11A
in transfected cells. The comparison of the effects of pre-miR-210 with those of a negative control
supports the sequence-specificity of the effects. It is important to underline that the K562(BCL11A-XL)
clone #12 was required for these experiments, since K562 cells do not express (or express at very low
level) BCL11A (see Figure 4A).
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Figure 5. Effects of pre-miR-210 on BCL11A-XL mRNA content and γ-globin gene expression. (A,B)
Effects of transfection with increasing amounts of pre-miR-210 and pre-miR-negative control (arrowed) on
BCL11A-XL mRNA (A) and γ-globin mRNA (B); The RNA was isolated after 48 h from the transfection
and the expression analyzed by RT-qPCR was expressed relative to treatment with the pre-miR-negative
control. ** p < 0.01; * p < 0.05 (n = 3); (C) Western blotting (a representative experiment on the left,
the analysis of three experiments on the right) performed on proteins isolated from cells treated as
indicated. Ribosomal S6 protein kinase (p70S6K) was used as internal control (* p < 0.05; n = 3).
2.5. Transfection of Erythroid Precursor Cells with Pre-miR-210 Leads to a Decrease of BCL11A-XL and an
Increase of γ-Globin mRNA
Erythroid precursor cells (ErPCs) from fourβ-thalassemia patients were isolated and cultured with
the two-phase procedure developed by Fibach et al. [42]. Two β◦-39/β◦-39, one β+-IVSI-6/β+-IVSI-6
and one β◦-39/β+-IVSI-110 were recruited, the endogenous levels of HbF were in their ErPCs within
a 25–45% range. After 14 days, cells were (a) untreated, (b) transfected with 200 nM pre-miR-210 or
(c) transfected with 200 nM of pre-miR negative control. After a further 120 h, BCL11A mRNA and
γ-globin mRNA content were determined by RT-qPCR. The results obtained are shown in Figure 6A
and clearly indicate that transfection with pre-miR-210 leads to decreased expression of BCL11A
mRNA (left side of the panel) and increased γ-globin mRNA content (middle side of the panel).
Moreover, ELISA testing demonstrates that fully in agreement with the repressor role of BCL11A in
γ-globin gene expression, the decrease of BCL11A gene expression is accompanied by an increase of
γ-globin (Figure 6A, right side of the panel).
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In order to verify whether the effects of the transfection with pre-miR-210 are restricted to BCL11A
and γ-globin gene expression, additional erythroid associated markers (CD71 and Glycophorin A),
were studied in transfected ErPCs. The data are shown in Figure 6B and demonstrate that no changes in
CD71 (Transferrin Receptor) and GPA were detectable when untreated ErPCs are compared with ErPCs
transfected with pre-miR-210 and a pre-miR-negative control. In particular, it should be underlined that
the treatment is not sufficient to induce the activation of the full program of erythroid differentiation.
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3. iscussion
The management of β-thalassemia patients is mostly based on blood transfusion, chelation therapy
and, alternatively, on bone marrow transplantation [24]. Recently, novel therapeutic options are
explored, such as gene therapy and fetal hemoglobin (HbF) induction [24–26,30,36]. Despite the fact that
these approaches are promising, these therapeutic strategies are at present still under deep experimental
development and are the basis of only a limited number of clinical trials. For instance, hydroxyurea,
the most used HbF inducer in β-thalassemia, exhibits the following limitations: (a) toxicity; (b) lack of
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response in about 50% of β-thalassemia patients; (c) development of drug-resistance under long-term
treatments. Therefore, the validation of new HbF inducers and/or new approaches for reactivation of
γ-globin genes are required to develop novel options in the therapy of β-thalassemia.
In this respect, the recent finding that the transcriptional regulation of γ-globin gene expression
is under the negative control of several transcriptional repressors (including MYB, BCL11A, KLF-1,
KLF-2, Sp1, LYAR) is of great interest. These evidences allow the identification of specific targets
for the development of possible strategies to reactivate γ-globin gene expression (and consequently
HbF production) by targeting repressors of γ-globin gene transcription. Among possible alternatives,
the use of microRNA-based approaches can be proposed. In fact, the involvement of miRNAs in
the control of transcriptional repressors of the human γ-globin genes has been firmly demonstrated.
Examples are miR-15a and miR-16-1 (targeting MYB mRNA), miR-486-3p (targeting BCL11A mRNA),
miR-23a (targeting KLF-2) and miR-27a (targeting Sp1).
With respect to other erythroid associated miRNAs, information is still lacking. One of the possible
microRNA involved in HbF production is miR-210. We have reported that miR-210 is involved in
erythroid differentiation and, possibly, in γ-globin gene up-regulation [19,20]. This finding has been
confirmed in other laboratories by Sarakul et al. [21], Bavelloni et al. [22] and Sawant et al. [23].
For instance, a recent paper by Bavelloni et al. confirmed a six-fold increase of miR-210 following
treatment of K562 cells with mithramycin. The result published by Sarakul demonstrated that
miR-210 was up-regulated in K562 and β-thalassemia/HbE progenitor cells cultured under hypoxic
condition. Inhibition of miR-210 expression leads to a reduction of the globin gene expression and
delayed maturation in K562 and erythroid progenitor cells, indicating that miR-210 contributes
to hypoxia-induced erythroid differentiation in both K562 cells and β-thalassemia/HbE erythroid
progenitor cells. The possible involvement of miR-210 in HbF production is also supported by the
recent communication by Sawant et al., suggesting that HbF induction by hydroxycarbamide works
through miR-210 in sickle cell anemia patients [23].
In the present study, we have identified a coding sequence of BCL11A mRNA as possible target
of miR-210. The following results sustain this hypothesis: (a) interactions between miR-210 and the
miR-210 BCL11A mRNA site were demonstrated by SPR-based biomolecular interaction analysis (BIA)
(see Figure 2B); (b) the miR-210 site of BCL11A-XL is conserved through molecular evolution, possibly
indicating that these sequences play key biological functions (see Figure 2A); (c) forced expression of
miR-210 leads to decrease of BCL11A mRNA and increase of γ-globin mRNA content in erythroid cells,
including erythroid precursors isolated from β-thalassemia patients (see Figures 4 and 5). However,
the effects of the transfection with pre-miR-210 are restricted to BCL11A and γ-globin gene expression,
and no changes of the other erythroid markers CD71 and GPA were detectable suggesting that the
treatment with pre-miR-210 is not sufficient to induce the activation of the full program of erythroid
differentiation and, therefore, should be combined with other inducers of erythroid differentiation in
order to fully induce HbF accumulation. Interestingly, decreases of BCL11A expression was found in
ErPCs from β-thalassemia patients treated with HU and MTH [41 and unpublished results] together
with the expected increase of γ-globin mRNA content, further supporting the role of this transcriptional
regulator and its modifiers.
While most of validated miRNA/mRNA interactions involve the 3′UTR of the target
mRNAs [33,34,43], functional interactions between microRNAs and coding sequences of target genes
have also been reported in several studies [44–46]. Our study suggests that, in addition to the already
reported binding of miR-486-3p to the 3′UTR sequence of the BCL11A mRNA, the coding mRNA
sequence of BCL11A can be targeted by miR-210 (see the scheme reported in Figure 7). In the
experimental approaches described, upregulation of γ-globin gene expression can be achieved by
different miRNA-based approaches, including the use of pre-miRNA targeting the 3′UTR region of
the BCL11A mRNA, or the use of pre-miR-210, possibly targeting the coding region. Both strategies,
that might involve different miRNAs and, at least in theory, can be combined in a “multi-miRNAs
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therapeutic approach” might lead to extensive BCL11A down-regulation and induction of γ-globin
gene expression, in consideration of the γ-globin genes repressor function of BCL11A.Int. J. Mol. Sci. 2017, 18, 2530 10 of 17 
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3 mM EDTA and 0.05% v/v Surfactant P20, pH 7.4) as running buffer as previously described [47,48].
In order to obtain an efficient capture of 5′-biotinylated oligonucleotide mimicking the miR-210
binding site of BCL11A mRNA onto the sensor chip, the well documented streptavidin-biotin
interaction was employed. To this aim, the sensor chip SA, precoated with streptavidin, was used.
After pretreatment with three 10 µL pulses with 50 mM NaOH–1 M NaCl, an injection of 10 ng/µL
biotinylated oligonucleotide carrying sequences mimicking the miR-210 binding site of the BCL11A
mRNA (IDT Integrated DNA Technologies, Coralville, IA, USA) was performed, followed by a wash
with 50 mM NaOH. Hybridization to the immobilized oligonucleotide was performed by a 20 µL
injection of 2.3 µM microRNA (miR-210, miR-221, miR-222, IDT), followed by a wash with 15 µL
HBS-EP+ buffer and a regeneration of the sensor chip with a 5 µL pulse of 50 mM NaOH. The Biacore™
X100 Control Software and Biacore™ X100 Evaluation Software, version 2.0.1 (GE Healthcare) were
used for operation and data analysis, respectively. Suitable blank control injections with running buffer
were performed, and the resulting sensorgrams were subtracted from the experimental sensorgrams.
4.3. Ethics Statement
The use of human material was approved by the Ethics Committee of Ferrara’s District, document
number 06/2013, approved on 20 June 2013. All samples of peripheral blood have been obtained after
receiving written informed consent from patients and healthy donors or their legal representatives.
4.4. Human Cell Lines and Culture Conditions
Human leukemia K562 [38,39] and K562(BCL11A-XL) cells [41,49,50] were cultured in humified
atmosphere of 5% CO2/air in RPMI 1640 medium (Sigma Aldrich, St. Louis, MO, USA) supplemented
with 10% FBS (Biowest, Nuaillé, France), 50 U/mL penicillin and 50 µg/mL streptomycin. Mithramycin
(MTH) [51,52], rapamycin (RAPA) [53], resveratrol (RVS) [54] and hydroxyurea (HU) [55] were
purchased from Sigma. Treatment of cells with erythroid differentiation inducers was carried out
by adding the appropriate drug concentrations at the beginning of the cultures (cells were seeded at
30,000/mL). The medium was not changed during the induction period. To determine possible
antiproliferative effects cell growth was studied by determining the cell number/mL using Z1
Coulter Counter (Coulter Electronics, Hialeah, FL, USA). Erythroid differentiated cells containing
hemoglobin were detected by specific reaction with a benzidine/hydrogen peroxide solution as
reported elsewhere [41,51]. The final concentration of benzidine was 0.2% in 5 M glacial acetic acid
and 10% H2O2. For the production of K562 cell clones with integrated copies of a BCL11A-XL
expressing vector we have transfected K562 cells with the pCDNA3.1-BCL11A-XL vector, and then
cloned the transfected cells by limiting dilutions and selected the clones in the presence of neomycin
as reported elsewhere [41].
4.5. Patients and Erythroid Precursor Cultures
Erythroid precursor cells isolated from β-thalassemia patients were isolated as described
elsewhere [42,53,54]. In this study two β◦-39/β◦-39, one β+-IVSI-6/β+-IVSI-6 and one β◦-39/β+-IVSI-110
were recruited and their isolated ErPCs employed. Written informed consent was obtained from
each patient and the samples of peripheral blood were collected just before the transfusion treatment.
The Ficoll-Hypaque density gradient centrifugation was used to purify peripheral blood mononuclear cells.
After isolation, the mononuclear cell layer was washed three times by adding 1× phosphate-buffered
saline (PBS) solution. The pellet was then resuspended in α-minimal essential medium supplemented
with 10% FBS (Celbio, Milano, Italy), 1 µg/mL cyclosporine A (Sigma Aldrich) and 10% conditioned
medium obtained from supernatant of the 5637 bladder carcinoma cell line culture. This mononuclear
cell suspension was grown in these culture conditions for seven days at 37 ◦C, under an atmosphere of
5% CO2 in air, with extra humidity (phase I culture) [42,49,50]. The nonadherent cells were harvested
from the flask, washed in 1× PBS, and then grown in α-medium, 30% FBS, 1% deionized bovine serum
albumin (BSA), 10−5 M β-mercaptoethanol, 1.5 mM L-glutamine, 10−6 M dexamethasone, and 1 U/mL
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human recombinant erythropoietin (EPO) (Tebu-bio, Magenta, Italy) and stem cell factor (SCF) (Inalco,
Milano, Italy) (phase II culture) [42,53,54]. After seven days of cell culture phase II, the cells were
treated for additional five days in the presence of 200 nM hsa-miR-210 pre-miR™ miRNA precursor
(PM10516, Ambion-ThermoFisher Scientific, Waltham, MA, USA) or Pre-miR™ miRNA Precursor
Negative Control #1 (Ambion-ThermoFisher Scientific).
4.6. Transfection Procedure
The protocol used for transfection of pre-miRs in K562 cells and in ErPCs was reported by Ambion
(Applied Biosystems, Foster City, CA, USA) and similar to that employed by Bianchi et al., taking
into account the fact that K562 cells are an “in vitro” established cell line, while ErPCs are “ex vivo”
primary erythroid precursors isolated from patients, needing of different experimental conditions for
optimal transfection [20]; 24-well plates were used and 30,000 cell/mL (K562) or 1,000,000 cell/mL
(ErPCs) were seeded. Cells transfections were performed using Lipofectamine RNAiMAX Transfection
Reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA) accordingly to manufacturer’s instruction,
with the indicated concentrations (range 30–270 nM) of hsa-miR-210 pre-miR™ miRNA precursor
(PM10516, Ambion-ThermoFisher Scientific). The transfection procedure with pre-miRs on the same
cells was repeated after two days. Pre-miR™ miRNA Precursor Negative Control #1 (AM17110
Ambion-ThermoFisher Scientific) was used as negative control.
4.7. RNA Extraction
Cells were isolated by centrifugation at 1500 rpm for 10 min at 4 ◦C, washed in PBS, lysed
in Tri-reagent™ (Sigma Aldrich), according to the manufacturer’s instructions. The isolated RNA
was washed once with cold 75% ethanol, dried and dissolved in diethylpyrocarbonate treated water
before use.
4.8. Reverse Transcription and Quantitative Real-Time PCR (RT-qPCR)
For gene expression analysis 300 ng of total RNA were reverse transcribed to cDNA using the
Taq-Man Reverse Transcription PCR Kit and random hexamers (Applied Biosystems) in a 50-µL
reaction. Real-time-qPCR experiments were carried out using 5′ nuclease assay with primers and
probes indicated in Table 2, purchased from Applied Biosystems (Applied Biosystems). Amplification
of γ-globin transcripts was achieved with primers and probes purchased from IDT (forward primer
5′-TGG CAA GAA GGT GCT GAC TTC-3′; reverse primer 5′-TCA CTC AGC TGG GCA AAG
G-3′; probe 5′-FAM-TGG GAG ATG CCA TAA AGC ACC TGG-TAMRA-3′). The cDNA (1 µL) was
amplified for 40 PCR cycles using the Taq-Man Universal PCR Master Mix 2X (Applied Biosystems) in
an CFX96 Touch Real-Time PCR Detection System (Biorad, Hercules, CA, USA). Relative expression
was calculated using the comparative cycle threshold method and the endogenous controls human 18S
rRNA and human RPL13A were used as normalizer genes. Duplicate negative controls (no template
cDNA) were also run with every experimental plate to assess specificity and to rule out contamination.
The real-time PCR reactions were performed in duplicates for both target and normalizer genes.
Table 2. TaqMan® Assays employed in Real-time quantitative PCR experiments (primers and probe sets).
Gene Name Gene Accession Number Assay Location Assay ID
BCL11A 1 NM_022893.3 Exons 1–2 Hs00256254_m1
BCL11A 2 NM_022893.3 Exons 4–4 Hs00250581_s1
18S Ribosomal RNA X03205.1 NA 4310893E
RPL13A 3 NM_012423.3 Exons 5–6 Hs03043885_g1
1 This assay was used for amplification of BCL11A transcripts in K562(BCL11A-XL) clones; 2 This assay was
used for amplification of BCL11A transcripts in erythroid precursor cells from β-thalassemia patients; 3 ribosomal
protein L13a.
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4.9. Western Blot
Cellular extracts were obtained using Pierce RIPA Buffer (Thermo Fisher Scientific, Waltham,
MA, USA) according to the manufacturer instructions and quantified using Pierce BCA Protein
Assay kit (Thermo Fisher Scientific). Twenty micrograms of protein cytoplasmic extracts were
denatured for 5 min at 98 ◦C in 1× sodium dodecyl sulfate (SDS) sample buffer (62.5 mM Tris–HCl
pH 6.8, 2% SDS, 50 mM dithiothreithol (DTT) 0.01% bromphenol blue, 10% glycerol), and loaded on
SDS–polyacrylamide gel in Tris–glycine buffer (25 mM Tris, 192 mM glycine, 0.1% SDS). Precision Plus
Protein WesternC Standards (size range: 10–250 kDa) (Bio-Rad) was used as standard to determine
molecular weight. Membrane was probed using the BCL11A primary rabbit monoclonal antibody
(1:10,000) (Cat. Ab191402, AbCam, Cambridge, UK). The day after, membrane was washed and
incubated with an appropriate HRP-conjugated secondary antibody (1:2000) and an HRP-conjugated
anti-biotin antibody (1:1000), used to detect biotinylated protein marker, and exposed to ECL film
(GE Healthcare, Little Chalfont, UK). After the stripping procedure membrane was re-probed with the
primary antibody against p70S6K (Catalog No. 2708, Cell Signaling, Leiden, Netherlands), used as
normalization control. Films for chemiluminescent blots were analyzed by Gel Doc 2000 (Bio-Rad)
using Quantity One program to elaborate the intensity data of our specific target protein.
4.10. Elisa Assay
Proteic extracts were obtained by the resuspension of cellular pellets in cold water, frozen by dry
ice for 5 min and vortexed for 10 s. This step was repeated five times consecutively. Samples were
finally centrifuged at 14,000× g for 15 min and the supernatant cytoplasmic fractions were collected
and immediately frozen at −80 ◦C. Aγ-globin ELISA was performed using cell lysates with the
Human Hemoglobin gamma 1 (HBg1) ELISA kit (MyBioSource, San Diego, CA, USA) according to the
manufacturer’s protocol.
4.11. FACS Analysis
The erythroid differentiation status of ErPCs was investigated by studying transferrin Receptor
(trfR) and glycophorin A (GPA) expression by fluorescence-activated cell sorting (FACS) analysis using
anti-human CD71 fluorescein isothiocyanate (FITC)-conjugated antibody (Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany) and anti-human CD235a (glycophorin A) phycoerythrin (PE)-conjugated
antibody (Miltenyi Biotec). According to the manufacturer’s protocol, 10 µL of antibodies were added
to freshly isolated cells in 100 µL 1× PBS and 1% FBS, and cells were incubated on ice for 30 min.
Cells were washed twice in 1× PBS and 1% FBS and analyzed using the BD FACS Canto II system
(Becton-Dickinson, Franklin Lakes, NJ, USA). Data were analyzed using FACSDiva 8.0 software
(Becton-Dickinson, Franklin Lakes, NJ, USA).
4.12. Statistical Analysis
All experimental data were normally distributed and presented as mean ± SD. Statistical
differences between groups were compared using one-way ANOVA software. p Values were obtained
using the Paired t-test of the GraphPad Prism Software. Statistical differences were considered
significant when p < 0.05 (*), highly significant when p < 0.01 (**).
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